Tenax en­dures (an­oth­er) clin­i­cal cat­a­stro­phe as its PhI­II flops, shares blitzed

An­oth­er biotech day, an­oth­er biotech mi­cro­cap dis­as­ter.

To­day’s turn goes to Tenax Ther­a­peu­tics $TENX, a Mor­risville, NC com­pa­ny which re­port­ed this morn­ing that its Phase III study of its lead drug lev­osi­men­dan “did not achieve sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tions in the dual end­point of death or use of a me­chan­i­cal as­sist de­vice at 30 days, nor in the quad end­point of death, my­ocar­dial in­farc­tion, need for dial­y­sis, or use of a me­chan­i­cal as­sist de­vice at 30 days.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER